ATC Group: B02BX07 Lusutrombopag

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B02BX07 in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B02 Antihemorrhagics
3 B02B Vitamin K and other hemostatics
4 B02BX Other systemic hemostatics
5 B02BX07

Active ingredients in B02BX07

Active Ingredient Description
Lusutrombopag

Lusutrombopag is an orally active TPO receptor agonist. Lusutrombopag acts on the haematopoietic stem cells and on the transmembrane domain of human TPO receptors expressed in megakaryocytes, to stimulate the megakaryocyte to proliferate and differentiate via the similar signal transduction pathway for up-regulating production used by endogenous TPO, thus leading to thrombocytopoiesis.

Related product monographs

Title Information Source Document Type  
MULPLEO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Estonia (EE)

Ireland (IE)

Italy (IT)

Lithuania (LT)

Poland (PL)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.